FOSUN HEALTH Logo

Pancreatic Cancer Prevention

catalogue

Pancreatic Cancer Prevention

Pancreatic Cancer Prevention

There is no screening programme for pancreatic cancer in the general population, and no diet that prevents it. What exists is a targeted surveillance pathway for a defined group at high inherited risk, and a clear set of reasons to investigate symptoms.

Starting with an honest risk picture

A risk assessment for pancreatic cancer produces three kinds of answer, and it is worth knowing which one applies before deciding what to do:

  • An inherited risk that warrants surveillance — a known alteration in BRCA1, BRCA2, PALB2, CDKN2A, ATM, STK11 or a hereditary pancreatitis gene, or a family history that meets a surveillance programme's criteria. This is the group for whom regular imaging is genuinely offered.
  • A precursor lesion that warrants surveillance — a mucinous cyst or an intraductal papillary mucinous neoplasm found incidentally, where the question is whether and when to remove it.
  • A raised risk that changes nothing practical — smoking, age, obesity, long-standing diabetes or chronic pancreatitis. These matter, but they do not make scanning asymptomatic people worthwhile.

The distinction is the whole point of the section. Being in the third group does not mean there is nothing to do — it means the useful action is stopping smoking and paying attention to symptoms, rather than having scans that are unlikely to find anything and may find something that would never have mattered.

Why there is no general screening test

Pancreatic cancer would seem an ideal target for screening: it is serious, it has a detectable precursor phase in some cases, and it is often diagnosed late. The reason screening is not recommended for the general population is arithmetic rather than indifference.

  • The disease is uncommon. Where the disease is rare, even a good test produces many false positives for every true case, and each false positive leads to more imaging, more endoscopy and sometimes to surgery on a normal pancreas.
  • Imaging cannot yet find it reliably at a curable stage. CT and MRI detect established tumours well; the small, early lesions that screening is meant to catch are harder, and endoscopic ultrasound — the most sensitive available test — is invasive and operator-dependent.
  • There is no blood test. CA19-9 is not a screening test: it can be normal in people who have the disease and raised in people who do not.
  • The ratio improves in high-risk groups. Where the pre-test probability is much higher, the same tests become worthwhile — which is precisely why surveillance exists, but only for a defined minority.

This is the same reasoning that applies to any screening programme: it is a decision about a population, not a judgement about an individual. A person with a strong family history is not being offered the same bargain as the general population.

Who is offered surveillance, and how

Where surveillance is offered, it follows a defined protocol rather than an open-ended series of scans. The details vary between programmes, and the following describes the shape of it:

  • Who — carriers of a relevant gene alteration, and people with a family history meeting the programme's criteria, usually two or more affected first-degree relatives, or one affected relative plus a carrier status.
  • When it starts — typically from around the age of 50, or ten years before the youngest affected relative was diagnosed, whichever comes first.
  • What is done — MRI with MRCP is the usual first-line test, because it detects cystic lesions and ductal changes without radiation; endoscopic ultrasound is used alongside or instead in some programmes.
  • How often — commonly annually, with the interval adjusted according to what is found. A stable normal pancreas and an unchanged small cyst do not lead to the same schedule.
  • What triggers an intervention — a new solid lesion, a growing cyst, or high-risk features such as a dilated main duct or an enhancing nodule within a cyst, which is when surgery is discussed.

Two things are worth being clear about. Surveillance is a specialist pathway, and entering it requires a referral rather than a self-directed decision to have annual scans. And surveillance does not guarantee that a cancer will be found early; it shifts the odds in a group whose odds are already unfavourable, which is all that can honestly be claimed for it.

If a relative has had pancreatic cancer

A family history changes the practical advice in two directions, and both are worth acting on.

The first is that relatives may be eligible for surveillance. Whether they are depends on the pattern — the number of affected first-degree relatives, the age at which they were diagnosed, and whether a gene alteration has been identified in the family. Where an alteration is known, testing relatives is straightforward; where no alteration is found, eligibility is judged on the family tree, which is why drawing an accurate one is worth the effort.

The second is that the patient should have genetic testing. A pancreatic cancer diagnosis in someone with a family history, or in someone diagnosed young, is a recognised reason to test for BRCA1, BRCA2, PALB2, CDKN2A, ATM and mismatch repair genes — because the result can change treatment. A BRCA or PALB2 alteration makes platinum chemotherapy and PARP inhibitor maintenance effective, and mismatch repair deficiency opens the possibility of immunotherapy. In that sense, taking a family history is not only about the relatives.

Smoking, weight and diet

The measures available to the general population are few, and it is more useful to state them plainly than to pad the list.

  • Not smoking is the measure with the clearest evidence — the risk rises with cumulative exposure and falls after stopping, and the benefit extends well beyond this one cancer.
  • Keeping weight within a healthy range is associated with a modestly lower risk, and with clear benefits for diabetes and cardiovascular disease regardless.
  • Limiting chronic heavy alcohol use is reasonable, particularly given its relationship with chronic pancreatitis.
  • Do not expect any diet to prevent this cancer. No food, supplement or dietary pattern has been shown to prevent pancreatic cancer, and claims to the contrary are not supported.

The reason this section is short is not that prevention is unimportant but that pancreatic cancer is not, in the ordinary sense, a preventable disease. Presenting diet and supplements as protective would be reassuring and false; the honest position is that a small number of measures reduce a risk that most people were never able to identify in the first place.

What prevention and surveillance cannot do

Being clear about the limits protects patients from two mistakes — expecting surveillance to guarantee early detection, and interpreting a clean scan as permanent reassurance.

  • Most people who develop pancreatic cancer have no risk factor, so a normal risk assessment is not protection.
  • Surveillance can miss a tumour between intervals, particularly a rapidly growing one that appears between annual scans.
  • A scan can find something that would never have caused harm — a small stable cyst, for example — and every subsequent test carries its own cost and anxiety.
  • Surveillance is not a substitute for investigating symptoms. New jaundice, persistent back pain or unexplained weight loss needs imaging now, whatever the last scan showed.

The last point is the one that matters most in practice. A patient in a surveillance programme who develops jaundice should not wait for the next scheduled scan, and a patient outside any programme who develops it should not be reassured by the absence of risk factors.

A plan you can act on

Laid out as actions rather than as a list of risks:

  • If you smoke, ask for help to stop — this is the single measure with the best evidence behind it.
  • If a first-degree relative has had pancreatic cancer, ask your clinician about referral for genetic counselling and whether a surveillance pathway applies to you.
  • If you already know you carry an alteration in BRCA1, BRCA2, PALB2, CDKN2A or ATM, ask specifically about pancreatic surveillance as well as the surveillance you may already have for other organs.
  • If you have been told you have a pancreatic cyst or an intraductal papillary mucinous neoplasm, ask what the surveillance interval is, what features would trigger surgery, and who is following it.
  • If you develop new jaundice, persistent back pain, unexplained weight loss, or new diabetes with weight loss, ask for imaging of the pancreas rather than waiting for the next appointment.

Each of these is a specific question with a specific route. None of them is a reason to have annual scans without an indication — which is the position most patients are actually in.

Frequently Asked Questions

Is there a blood test that screens for pancreatic cancer?

No. CA19-9 is the marker usually discussed, and it is not suitable for screening: it can be normal in people who have the disease, including those who are Lewis-antigen negative, and it is raised by any obstruction of the bile duct, including benign ones. It is used as a baseline and as a trend once pancreatic cancer is suspected or confirmed, not to decide whether to look.

Should I have a scan every year because my father had pancreatic cancer?

Not automatically — it depends on the pattern in your family and on whether a gene alteration has been identified. Surveillance programmes consider people with a relevant alteration, or with two or more affected first-degree relatives, or one affected relative together with carrier status. Where it applies, surveillance usually starts around the age of 50, or ten years before the youngest affected relative was diagnosed. If your father was the only affected person and no alteration has been found, the useful step is a discussion with a genetic counsellor rather than self-directed scanning.

Can a pancreatic cyst become cancer?

Some can, and the risk varies a great deal by type. Mucinous cysts and intraductal papillary mucinous neoplasms carry the potential to become invasive, while serous cysts essentially do not. The features that matter are the size, whether the main pancreatic duct is dilated, and whether there is an enhancing nodule inside the cyst. That is why the question for a person with a cyst is not whether it is dangerous but what the specific features indicate and who is tracking the interval.

Does stopping smoking reduce the risk?

Yes, although the risk does not return to that of a lifelong non-smoker immediately. The association is dose-dependent, so risk rises with the number of cigarettes and the years of smoking, and it declines after stopping over a period of years. Stopping also reduces the risk of several other cancers and of cardiovascular and respiratory disease, so the overall case for stopping does not rest on the pancreatic cancer risk alone.

Patient Stories

Stories from our pancreatic cancer programme, pulled automatically from the patient story library by disease tag.

View all patient stories →

A family history, a pancreatic cyst, or a gene result to interpret?

Send the family history in as much detail as you have, any genetic test results, and the reports of any pancreatic imaging or cyst surveillance already done. Our team will say whether a surveillance pathway applies and what interval is appropriate, with a written assessment within 48 hours of the file being complete.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*